Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
AAM Urges Congress To Re-evaluate Blocking Act
Report Claims Legislation Could Cost $1.7bn For Each Generic Delayed
The Blocking Act may “cause delays in generic entry and significant missed savings opportunities” • Source: Shutterstock
More from Policy & Regulation
More from Generics Bulletin